New blood test could spot hidden tumors causing high blood pressure

NCT ID NCT01022515

Completed Diagnosis Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new blood marker called EM66 can help doctors tell the difference between high blood pressure caused by rare adrenal tumors (pheochromocytoma or paraganglioma) and regular high blood pressure. Researchers measured EM66 levels in 60 adults with either these tumors or essential hypertension. The goal is to improve diagnosis and avoid unnecessary tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION PARAGANGLIOMA PHEOCHROMOCYTOMA

Contacts and locations

Locations

CIC 9301

Lille, 59000, France
CIC 9304

Paris, 75012, France
Cardiology Department

Paris, 75012, France
Cic-Crb 0204

Rouen, 76000, France
Endocrinology Department

Lille, 59000, France
Endocrinology Department

Rouen, 76000, France
Endocrinology Department, Gustave-Roussy Institute

Villejuif, 94000, France
Inserm U982/EA 4310; Rouen University (DC2N)

Mont-Saint-Aignan, 76800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.